Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Pfizer
Study ID
NCT05462639
Status
No Longer Available

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity. This expanded access protocol will provide access to elranatamab until it becomes commercially accessible to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.

Key Dates

Status verified
Aug 2024

Locations (33)

FacilityCityStateZIPSite coordinators
Ronald Reagan UCLA Medical CenterLos AngelesCalifornia90095-
UCLA Hematology/Oncology - Westwood (Building 200 Suite 120)Los AngelesCalifornia90095-
UC Irvine HealthOrangeCalifornia92868-
UC Irvine Medical CenterOrangeCalifornia92868-
Baptist Hospital of MiamiMiamiFlorida33176-
Miami Cancer InstituteMiamiFlorida33176-
Memorial Cancer Institute at Memorial Hospital WestPembroke PinesFlorida33021-
Memorial Cancer Institute at Memorial Hospital WestPembroke PinesFlorida33026-
Memorial Cancer Institute at Memorial Hospital WestPembroke PinesFlorida33028-
Memorial Hospital West Laboratory ServicesPembroke PinesFlorida33028-
Blood and Marrow Transplant Group of GeorgiaAtlantaGeorgia30342-
Northside HospitalAtlantaGeorgia30342-
Georgia Cancer Center at Augusta UniversityAugustaGeorgia30912-
Franciscan HealthIndianapolisIndiana46237-
University of Mississippi Medical CenterJacksonMississippi39213-
University of Mississippi Medical CenterJacksonMississippi39216-
MSK Basking RidgeBasking RidgeNew Jersey07920-
John Theurer Cancer Center at Hackensack University Medical CenterHackensackNew Jersey07601-
MSK MonmouthMiddletownNew Jersey07748-
MSK BergenMontvaleNew Jersey07645-
MSK CommackCommackNew York11725-
MSK WestchesterHarrisonNew York10604-
Memorial Sloan Kettering Cancer CenterLong Island CityNew York11101-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).New YorkNew York10021-
Weill Cornell Medical CollegeNew YorkNew York10065-
MSK NassauUniondaleNew York11553-
OhioHealth Arthur G.H. Bing, MD Cancer CenterColumbusOhio43214-
OhioHealth Research InstituteColumbusOhio43214-
Baylor Scott & White Charles A. Sammons Cancer CenterDallasTexas75246-
Baylor University Medical CenterDallasTexas75246-
Baylor University Medical Center, Investigational Drug Services, Department of PharmacyDallasTexas75246-
Texas OncologyDallasTexas75246-

Find similar trials in Los Angeles, CA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Ronald Reagan UCLA Medical Center· Los Angeles, CAUCLA Hematology/Oncology - Westwood (Building 200 Suite 120)· Los Angeles, CAUC Irvine Health· Orange, CAUC Irvine Medical Center· Orange, CABaptist Hospital of Miami· Miami, FLMiami Cancer Institute· Miami, FL

Related Studies